DOV Pharmaceutical To Present In Amsterdam At The 18th Congress Of The European College Of Neuropsychopharmacology (ECNP)
HACKENSACK, N.J., Oct. 21 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced today that its SVP, Research and Chief Scientific Officer, Dr. Phil Skolnick, will present a lecture entitled "Strategies for the Development of Novel Antidepressants" on October 24, 2005, at the 18th Congress of the European College of Neuropsychopharmacology in Amsterdam, The Netherlands. Dr. Skolnick's lecture will focus on novel approaches for the treatment of depression. He will discuss the concept of the "broad spectrum" antidepressant, capable of simultaneously inhibiting the reuptake of norepinephrine, serotonin and dopamine, the three neurotransmitters most closely linked to depression. Dr. Skolnick will also discuss approaches that may circumvent the monoaminergic synapse.
The presentation will be archived and available in the investor relations section of DOV's website: http://www.dovpharm.com after the conference for 90 days.
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system and other disorders, including cardiovascular, that involve alterations in neuronal processing. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain, anxiety and depression. Our partner Neurocrine has filed two NDA's for the use of DOV's compound indiplon for the treatment of insomnia.DOV Pharmaceutical, Inc.
CONTACT: Alan Beckhard, Manager, Investor Relations and CorporateCommunications, of DOV Pharmaceutical, Inc., +1-201-968-0980
Web site: http://www.dovpharm.com/